Cryo-Cell International, Inc. (CCEL) 株式分析

企業概要

Cryo-Cell International, Inc. is an entity dedicated to the provision of cord blood and cord tissue cryopreservation services within the United States, specializing in cellular processing and cryogenic storage intended primarily for family use regarding umbilical cord blood and tissue stem cells. This business operates within the Healthcare sector, specifically classified under the Medical Care Facilities industry, which encompasses a range of services focused on patient care and specialized medical treatments. The company currently maintains a market capitalization of $29.80M, generates annual revenue of $31.57M, and employs a workforce of 72 individuals. These financial figures indicate that the company operates on a small-cap scale with a revenue base that suggests a niche market position rather than broad-scale commercial dominance. The modest employee count relative to the revenue generated implies a labor-intensive operational model or significant reliance on specialized, high-cost cellular processing technologies. The valuation reflects a mid-market profile where growth potential is weighed against the capital requirements necessary to maintain cryogenic storage facilities and regulatory compliance.

財務健全性

The company reported a trailing twelve-month revenue of $31.57M alongside a net income of $-2,429,385 and an EBITDA of $1.47M. The substantial gap between the positive revenue and the negative net income reveals a significant cost structure burden, likely driven by high operating expenses that consume nearly 78% of gross revenue before reaching the bottom line. Despite the net loss, the business generated positive free cash flow of $580,321, which indicates a degree of financial flexibility allowing for operational continuity despite accounting losses. Analyzing the profitability metrics shows a gross margin of 62.8%, suggesting efficient production costs for the cryopreservation services, yet this is offset by an operating margin of -50.6% and a profit margin of -7.7%. The wide disparity between gross and operating margins highlights significant overhead costs associated with facility maintenance, regulatory adherence, and administrative functions. On the balance sheet side, the company holds cash assets of $3.30M against total debt obligations of $11.56M, resulting in a negative price-to-book ratio of -1.60 which reflects the leverage position. Although the debt-to-equity ratio is listed as N/A due to negative equity, the current debt load exceeds cash reserves by a factor of approximately 3.5 times. Liquidity is constrained as indicated by a current ratio of 0.59, signaling that the company's current assets are insufficient to cover its short-term liabilities without external financing. Return on Equity is N/A due to the negative equity base, while Return on Assets stands at 0.5%, indicating minimal asset utilization efficiency relative to the asset base employed.

バリュエーション評価

Valuation multiples for Cryo-Cell International, Inc. include a trailing P/E ratio of N/A and a forward P/E of 46.25, implying that the market is pricing in significant future earnings recovery that has not yet materialized in current results. The price-to-book ratio of -1.60 indicates that the stock trades at a negative premium to book value, a condition typical for biotechnology firms with negative equity but potential future growth assets. Alternative valuation metrics such as a price-to-sales ratio of 0.94 and an EV/EBITDA of 25.94 suggest the market is valuing the company primarily on its sales volume and operational cash generation rather than current profitability. The stock price has fluctuated within a 52-week range defined by a high of $6.35 and a low of $2.72. Based on the provided data points, the current market price sits at the lower end of this range, trading at approximately 57% below the 52-week high if assuming a price near the lower bound, though the exact current price is not explicitly listed in the facts. The beta of 0.63 demonstrates that the stock exhibits lower volatility relative to the broader market, moving roughly 37% less than the market average during periods of fluctuation. This low beta suggests the asset may serve as a defensive holding within a diversified portfolio despite its high forward multiple.

Growth & Income

Revenue growth for the trailing twelve months stood at -2.3%, while earnings growth is listed as N/A due to the negative income position. The decline in revenue suggests a contraction in demand or pricing pressure, and since earnings are negative, the concept of earnings growing faster or slower than revenue is currently moot until profitability is restored. The company does not pay a sustainable dividend, evidenced by a dividend yield of 16.2% paired with an unsustainable payout ratio of 3962.9%. Such an extreme payout ratio indicates that the dividend is being paid from capital or cash reserves rather than earnings, making it mathematically unsustainable given the negative net income of $-2,429,385. Consequently, the company reinvests any available cash flow or relies on external capital to fund operations rather than distributing income to shareholders. The overall growth and income profile reflects a high-risk, low-yield characteristic common in early-stage or loss-making biotech companies where income is generated through capital appreciation expectations rather than dividend distributions.